2026 NPPES data Research Study Specialist NPI 1831159649 MD
Verify on CMS →

ANTHONY SZEMA, MD

Research Study Specialist in SOUTH SETAUKET, New York. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
492
Medicare Part D claims · 129 beneficiaries · Research Study Specialist avg: 601
Generic prescribing
40%
generic claims · 60% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$39.86
1 payments · CMS Open Payments (Sunshine Act)
What the federal data reveals: ANTHONY SZEMA, MD is a Research Study Specialist ([object Object]) practicing in SOUTH SETAUKET, New York with a Medicare Part D prescribing footprint of 492 claims across 129 beneficiaries — 60% brand-name prescribing . Industry payments of $39.86 across 1 transactions are disclosed under CMS Open Payments (Sunshine Act).

What stands out: ANTHONY SZEMA, MD filed 492 Medicare Part D claims in 2023 across SOUTH SETAUKET, New York. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.

ANTHONY SZEMA, MD at a glance

Quality data not reported

NPI registry status

Active

Issued 03/24/2006

NPI 1831159649

Primary specialty

Research Study Specialist

Rare

472 US NPIs in this specialty

Medicare Part D claims

492 18% vs specialty avg

2023 prescription claims

Specialty avg: 601

Specialty distribution in New York

How Research Study Specialist compares to other specialties among New York providers

New York providers

Research Study Specialist share within New York

1. Research Study Specialist42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Research Study Specialist share within New York

Specialty board-certification context

Estimated specialty board-certified rate — Research Study Specialist (ABMS / AOA reference)

Quality data not reported
Est. board-certified rate
78%
Research Study Specialist ABMS/AOA estimate

Est. board-certified rate (Research Study Specialist) — ABMS / AOA estimate

0%100%78%
Est. board-certified rate (Research Study Specialist) — ABMS / AOA estimate

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

ANTHONY SZEMA, MD is a Research Study Specialist provider practicing in SOUTH SETAUKET, New York, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: MD. NPI: 1831159649. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

ANTHONY SZEMA, MD appears in the CMS NPPES registry as a Research Study Specialist provider holding MD credentials at 3771 NESCONSET HWY, SOUTH SETAUKET, NY, 11720, with a listed phone of (631) 675-6474. NPI 1831159649 was issued on 03/24/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what SZEMA most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 492 prescription claims written by this provider, covering 129 Medicare beneficiaries and totaling roughly $1.6 million in drug spend, split 60% brand-name and 40% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.

Research Study Specialist is a narrow specialty nationwide, with 472 enrolled providers across 41 states and an average of 601 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

3771 NESCONSET HWY
SOUTH SETAUKET, NY 11720

Provider Details

NPI 1831159649
Specialty Research Study Specialist
Credentials MD
Gender Male
NPI Issued 03/24/2006

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for ANTHONY SZEMA, MD. Source: openpaymentsdata.cms.gov.

Total received

$40

Largest payer

GlaxoSmithKline, LLC.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — New York NYSBPMC 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 — they are NOT specific to ANTHONY SZEMA, MD. To verify ANTHONY SZEMA, MD's current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

312
Total board actions, New York 2023
Across 302 cases
3.12
Actions per 1,000 licensees
New York statewide rate
probation
Most common action type
89 cases

NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Brand-heavy

ANTHONY SZEMA, MD — brand share 60.0%
Specialty average (est.)

60% brand-name claims vs 40% generic, on 492 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

492
Total Claims
$1.6M
Total Drug Cost
129
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
901
Total Day Supply
24,881
Brand vs Generic
60% brand / 40% generic
Brand Drug Cost
$1.3M

Patient Demographics

Average Patient Age
72.6 years
Avg HCC Risk Score
1.06
Gender Split
70% female / 30% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Epinephrine
81
Albuterol Sulfate Hfa
Albuterol Sulfate
70
Trelegy Ellipta
Fluticasone/Umeclidin/Vilanter
47
Symbicort
Budesonide/Formoterol Fumarate
35
Ipratropium Bromide
25
Montelukast Sodium
25
Prednisone
23
Fasenra
Benralizumab
19
Xolair
Omalizumab
16
Advair Diskus
Fluticasone Propion/Salmeterol
15

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Research Study Specialist Overview

How ANTHONY SZEMA, MD fits within the Research Study Specialist landscape nationally.

472
Research Study Specialist Providers in US
41
States with Research Study Specialist
601
Avg Claims per Provider

ANTHONY SZEMA, MD's 492 claims are below the specialty average of 601.

Nearby Research Study Specialist Providers in New York

Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as SZEMA.

Compare Research Study Specialist nationally: see state-by-state distribution →

Frequently Asked Questions

What is ANTHONY SZEMA, MD's specialty?
ANTHONY SZEMA, MD specializes in Research Study Specialist and practices in SOUTH SETAUKET, New York. Credentials: MD.
How much does ANTHONY SZEMA, MD prescribe under Medicare Part D?
In 2023, ANTHONY SZEMA, MD wrote 492 Medicare Part D claims totaling $1.6M in drug costs for 129 beneficiaries.
Where is ANTHONY SZEMA, MD located?
ANTHONY SZEMA, MD is located at 3771 NESCONSET HWY, SOUTH SETAUKET, NY, 11720. Phone: (631) 675-6474.
What is ANTHONY SZEMA, MD's NPI number?
ANTHONY SZEMA, MD's National Provider Identifier (NPI) is 1831159649, issued on 03/24/2006.
Does ANTHONY SZEMA, MD prescribe more brand-name or generic drugs?
ANTHONY SZEMA, MD's prescribing is 60% brand-name and 40% generic drugs by claim count, with $1.3M in brand drug costs.
How many Research Study Specialist providers are there in the US?
There are 472 Research Study Specialist providers across 41 states in the US. The average Research Study Specialist provider writes 601 Medicare Part D claims per year.
What drugs does ANTHONY SZEMA, MD prescribe most often?
Based on 2023 Medicare Part D data, ANTHONY SZEMA, MD's most frequently prescribed drugs include Epinephrine, Albuterol Sulfate Hfa, Trelegy Ellipta. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does ANTHONY SZEMA, MD accept Medicare?
ANTHONY SZEMA, MD appears in CMS Medicare data with 492 Part D claims and 129 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify ANTHONY SZEMA, MD's credentials?
ANTHONY SZEMA, MD's NPI is 1831159649 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology